Literature DB >> 28523108

2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors.

Cheng Mo1,2, Zhang Zhang3, Christopher P Guise4,5, Xueqiang Li1,2, Jinfeng Luo1, Zhengchao Tu1, Yong Xu1, Adam V Patterson4,5, Jeff B Smaill4,5, Xiaomei Ren3, Xiaoyun Lu3, Ke Ding3.   

Abstract

A series of 2-aminopyrimidine derivatives were designed and synthesized as highly selective FGFR4 inhibitors. One of the most promising compounds 2n tightly bound FGFR4 with a Kd value of 3.3 nM and potently inhibited its enzymatic activity with an IC50 value of 2.6 nM, but completely spared FGFR1/2/3. The compound selectively suppressed proliferation of breast cancer cells harboring dysregulated FGFR4 signaling with an IC50 value of 0.38 μM. Furthermore, 2n exhibited extraordinary target specificity in a Kinome-wide screen against 468 kinases, with S(35) and S(10) selectivity scores of 0.01 and 0.007 at 1.0 μM, respectively.

Entities:  

Keywords:  Selective FGFR4 inhibitor; breast cancer; hepatocellular carcinoma; targeted therapy

Year:  2017        PMID: 28523108      PMCID: PMC5430393          DOI: 10.1021/acsmedchemlett.7b00091

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  27 in total

Review 1.  Targeting FGFR Signaling in Cancer.

Authors:  Mehdi Touat; Ecaterina Ileana; Sophie Postel-Vinay; Fabrice André; Jean-Charles Soria
Journal:  Clin Cancer Res       Date:  2015-06-15       Impact factor: 12.531

2.  FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4.

Authors:  M H Xie; I Holcomb; B Deuel; P Dowd; A Huang; A Vagts; J Foster; J Liang; J Brush; Q Gu; K Hillan; A Goddard; A L Gurney
Journal:  Cytokine       Date:  1999-10       Impact factor: 3.861

3.  Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele.

Authors:  Johannes Bange; Dieter Prechtl; Yuri Cheburkin; Katja Specht; Nadia Harbeck; Manfred Schmitt; Tatjana Knyazeva; Susanne Müller; Silvia Gärtner; Irmi Sures; Hongyang Wang; Evgeny Imyanitov; Hans-Ulrich Häring; Pjotr Knayzev; Stefano Iacobelli; Heinz Höfler; Axel Ullrich
Journal:  Cancer Res       Date:  2002-02-01       Impact factor: 12.701

4.  Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma.

Authors:  Jiyeon Hyeon; Soomin Ahn; Jae Jun Lee; Dae Hyun Song; Cheol-Keun Park
Journal:  Dig Dis Sci       Date:  2013-03-02       Impact factor: 3.199

5.  Escape from flatland: increasing saturation as an approach to improving clinical success.

Authors:  Frank Lovering; Jack Bikker; Christine Humblet
Journal:  J Med Chem       Date:  2009-11-12       Impact factor: 7.446

6.  Liver-specific activities of FGF19 require Klotho beta.

Authors:  Benjamin C Lin; Manping Wang; Craig Blackmore; Luc R Desnoyers
Journal:  J Biol Chem       Date:  2007-07-11       Impact factor: 5.157

7.  High fibroblast growth factor 19 (FGF19) expression predicts worse prognosis in invasive ductal carcinoma of breast.

Authors:  Abdelbaset Buhmeida; Ashraf Dallol; Adnan Merdad; Jaudah Al-Maghrabi; Mamdooh A Gari; Muhammad M Abu-Elmagd; Adeel G Chaudhary; Adel M Abuzenadah; Taoufik Nedjadi; Eramah Ermiah; Fatima Al-Thubaity; Mohammed H Al-Qahtani
Journal:  Tumour Biol       Date:  2013-11-19

8.  Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention.

Authors:  Han Kiat Ho; Sharon Pok; Sylvia Streit; Jens E Ruhe; Stefan Hart; Kah Suan Lim; Hooi Linn Loo; Myat Oo Aung; Seng Gee Lim; Axel Ullrich
Journal:  J Hepatol       Date:  2008-10-12       Impact factor: 25.083

9.  Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma.

Authors:  Weijie Poh; Winnie Wong; Huimin Ong; Myat Oo Aung; Seng Gee Lim; Boon Tin Chua; Han Kiat Ho
Journal:  Mol Cancer       Date:  2012-03-23       Impact factor: 27.401

10.  Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival.

Authors:  Kai Hung Tiong; Boon Shing Tan; Heng Lungh Choo; Felicia Fei-Lei Chung; Ling-Wei Hii; Si Hoey Tan; Nelson Tze Woei Khor; Shew Fung Wong; Sze-Jia See; Yuen-Fen Tan; Rozita Rosli; Soon-Keng Cheong; Chee-Onn Leong
Journal:  Oncotarget       Date:  2016-09-06
View more
  9 in total

1.  Rotational Freedom, Steric Hindrance, and Protein Dynamics Explain BLU554 Selectivity for the Hinge Cysteine of FGFR4.

Authors:  Xiaojing Lin; Yuliana Yosaatmadja; Maria Kalyukina; Martin J Middleditch; Zhen Zhang; Xiaoyun Lu; Ke Ding; Adam V Patterson; Jeff B Smaill; Christopher J Squire
Journal:  ACS Med Chem Lett       Date:  2019-07-03       Impact factor: 4.345

2.  Approaches to selective fibroblast growth factor receptor 4 inhibition through targeting the ATP-pocket middle-hinge region.

Authors:  Robin A Fairhurst; Thomas Knoepfel; Catherine Leblanc; Nicole Buschmann; Christoph Gaul; Jutta Blank; Inga Galuba; Jörg Trappe; Chao Zou; Johannes Voshol; Christine Genick; Peggy Brunet-Lefeuvre; Francis Bitsch; Diana Graus-Porta; Pascal Furet
Journal:  Medchemcomm       Date:  2017-06-08       Impact factor: 3.597

3.  Investigation of Covalent Warheads in the Design of 2-Aminopyrimidine-based FGFR4 Inhibitors.

Authors:  Wuqing Deng; Xiaojuan Chen; Kaili Jiang; Xiaojuan Song; Minhao Huang; Zheng-Chao Tu; Zhang Zhang; Xiaojing Lin; Raquel Ortega; Adam V Patterson; Jeff B Smaill; Ke Ding; Suming Chen; Yongheng Chen; Xiaoyun Lu
Journal:  ACS Med Chem Lett       Date:  2021-03-22       Impact factor: 4.345

4.  FGFR4 phosphorylates MST1 to confer breast cancer cells resistance to MST1/2-dependent apoptosis.

Authors:  S Pauliina Turunen; Pernilla von Nandelstadh; Tiina Öhman; Erika Gucciardo; Brinton Seashore-Ludlow; Beatriz Martins; Ville Rantanen; Huini Li; Katrin Höpfner; Päivi Östling; Markku Varjosalo; Kaisa Lehti
Journal:  Cell Death Differ       Date:  2019-03-22       Impact factor: 15.828

Review 5.  FGFR-TKI resistance in cancer: current status and perspectives.

Authors:  Sitong Yue; Yukun Li; Xiaojuan Chen; Juan Wang; Meixiang Li; Yongheng Chen; Daichao Wu
Journal:  J Hematol Oncol       Date:  2021-02-10       Impact factor: 17.388

6.  6-Amino-2,4,5-trimethylpyridin-3-ol and 2-amino-4,6-dimethylpyrimidin-5-ol derivatives as selective fibroblast growth factor receptor 4 inhibitors: design, synthesis, molecular docking, and anti-hepatocellular carcinoma efficacy evaluation.

Authors:  Chhabi Lal Chaudhary; Dongchul Lim; Prakash Chaudhary; Diwakar Guragain; Bhuwan Prasad Awasthi; Hee Dong Park; Jung-Ae Kim; Byeong-Seon Jeong
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.051

7.  Computational Simulation Studies on the Binding Selectivity of 1-(1H-Benzimidazol-5-yl)-5-aminopyrazoles in Complexes with FGFR1 and FGFR4.

Authors:  You-Lu Pan; Yan-Ling Liu; Jian-Zhong Chen
Journal:  Molecules       Date:  2018-03-27       Impact factor: 4.411

8.  Design, Synthesis, Biological Evaluation, and Molecular Modeling of 2-Difluoromethylbenzimidazole Derivatives as Potential PI3Kα Inhibitors.

Authors:  Xiangcong Wang; Moxuan Zhang; Ranran Zhu; Zhongshan Wu; Fanhong Wu; Zhonghua Wang; Yanyan Yu
Journal:  Molecules       Date:  2022-01-08       Impact factor: 4.411

9.  GZD824 overcomes FGFR1-V561F/M mutant resistance in vitro and in vivo.

Authors:  Kaili Jiang; Xia Tang; Jing Guo; Rui He; Shingpan Chan; Xiaojuan Song; Zhengchao Tu; Yuting Wang; Xiaomei Ren; Ke Ding; Zhang Zhang
Journal:  Cancer Med       Date:  2021-06-10       Impact factor: 4.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.